High Throughput Screening

点击翻译按钮获取中文摘要

The High Throughput Screening Core (HTS) supports basic and translational biomedical research by designing, optimizing, and running high throughput assays that deliver potential therapeutics for cancer. This is done by integrating robotics, detection systems, chemical /biologics libraries and data management with expertise in optimizing technologies and outcomes along each step in the process. HTS provides Holden Comprehensive Cancer Center (HCCC) members with scalable early, pre-clinical development of therapeutics, including small molecule therapeutics, antibodies, siRNAs, antisense oligonucleotides and other biologics including patient-derived cell therapeutics. It also supports high throughput screening for studies exploring the biology of cancer. The HTS is equipped to perform high-throughput screening in 96-, 384- and 1536- well formats, with plate reader detection (Perkin-Elmer EnVision) using absorbance, fluorescence and luminescence, including advanced FRET and BRET techniques. HTS can also perform high content screening (HCS, Perkin-Elmer Operetta Confocal Imaging System) to detect and quantify phenotypic changes, i.e., cell differentiation, cell migration, neurite outgrowth, and target trafficking or by fluorescence intensities for target protein expression, transcription factor or signaling pathway analysis.